📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-20 17:15
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
₹1 Cr Related Party Loan and Name Change Proposed by Arunjyoti Bio Ventures
Arunjyoti Bio Ventures has released its FY 2025-26 Annual Report, proposing a name change to 'Pasura Industries Limited'. The company is seeking shareholder approval to ratify a ₹1.00 Cr loan to related party Pasura Xpress LLP and to waive the recovery of ₹25.19 lakh in excess managerial remuneration paid to two directors. Furthermore, a significant salary hike for the Whole-time Director to ₹8 lakh per month (plus ₹10 lakh annual LTA) is proposed, which is notable given the company reported a net loss of ₹5.4 Cr in the March 2026 quarter.
Confidence: HIGH
What changedThe company is undergoing a rebranding to Pasura Industries and formalizing financial support to a related party entity while seeking to increase executive pay.
Why it mattersThe name change indicates a strategic alignment with the 'Pasura' brand, but the related party loan and executive pay hikes during a period of financial losses (₹5.4 Cr loss in Q4 FY26) raise governance considerations.
Related party loan limit: ₹1,00,00,000Loan vs Net Worth: ~3.4%Excess remuneration waiver (Total): ₹25,19,232Proposed WTD Monthly Salary: ₹8,00,000FY25 Revenue: ₹27.88 Cr
📅 Short termThe stock may see neutral to cautious sentiment as investors digest the governance implications of the proposed remuneration hikes and related party transactions.
📈 Long termStructural significance depends on whether the rebranding and management changes lead to a turnaround from recent losses; otherwise, the increased cost base may pressure margins.
⚠ Risk flags
- Related-party transaction (₹1 Cr loan)
- Managerial remuneration hike despite recent quarterly losses
- High debt-to-equity ratio (0.78)
Key Highlights
Proposed name change from Arunjyoti Bio Ventures Limited to Pasura Industries Limited
Ratification of a loan up to ₹1,00,00,000 to related party Pasura Xpress LLP
Waiver of recovery for ₹25,19,232 in excess managerial remuneration paid during FY 2025-26
Proposed increase in Whole-time Director salary to ₹8,00,000 per month plus ₹10,00,000 annual LTA
40th Annual General Meeting (AGM) scheduled for August 12, 2026
👀 What to Watch
Investors should monitor the AGM voting results on August 12, 2026, specifically focusing on the approval of the related party loan and the substantial increase in executive compensation relative to the company's recent loss-making performance.
Arunjyoti Bio Ventures to Rename as Pasura Industries; Proposes ₹1 Cr Related Party Loan
Arunjyoti Bio Ventures has scheduled its 40th AGM for August 12, 2026, with a primary agenda to rename the company to Pasura Industries Limited. The board is seeking shareholder approval to ratify a ₹1.00 crore loan to related party Pasura Xpress LLP. Additionally, the company proposes waiving the recovery of ₹25.19 lakhs in excess remuneration paid to two directors and increasing the Whole-time Director's salary to ₹8.00 lakhs per month, despite a net loss of ₹5.4 crore in the March 2026 quarter.
Confidence: HIGH
What changedThe company is undergoing a formal rebranding to Pasura Industries and seeking to formalize related-party financial support and higher executive pay structures.
Why it mattersThe rebranding suggests a strategic alignment with the 'Pasura' brand, but the increase in executive compensation and related-party loans during a loss-making period (₹5.4 Cr loss in Mar 2026) raises governance questions for minority shareholders.
Related party loan limit: ₹1,00,00,000Total remuneration waiver: ₹25,19,232Proposed monthly salary (Director): ₹8,00,000Loan vs Net Worth: ~3.4%Mar 2026 Net Loss: ₹5.4 Cr
📅 Short termThe stock may see neutral to cautious sentiment as the market evaluates the governance implications of the AGM agenda items.
📈 Long termThe structural shift to the Pasura brand is significant, but long-term value depends on reversing recent losses and managing the high debt levels (₹22 Cr).
⚠ Risk flags
- Related-party transactions
- High executive remuneration relative to net profit
- Recent significant quarterly losses
- High debt-to-equity ratio
Key Highlights
Proposed name change from Arunjyoti Bio Ventures Limited to Pasura Industries Limited
Ratification of a loan up to ₹1,00,00,000 to related party Pasura Xpress LLP
Waiver of recovery for ₹25,19,232 in total excess managerial remuneration paid in FY26
Proposed salary hike for Whole-time Director to ₹8,00,000 per month plus ₹10,00,000 annual LTA
Appointment of Vivek Surana & Associates as Secretarial Auditors for a 5-year term
👀 What to Watch
Investors should monitor the AGM voting results, specifically the resolutions regarding related-party loans and executive compensation, given the company's recent quarterly losses and high debt-to-equity ratio of 0.78.
Arunjyoti Bio Q1 Profit Drops 70% to ₹61.24 Lakhs; Proposes Name Change to Pasura Industries
Arunjyoti Bio Ventures reported a weak Q1 FY27 with revenue declining 5.9% YoY to ₹8.20 crore and net profit falling sharply by 70% to ₹61.24 lakhs. The Board has proposed rebranding the company to 'Pasura Industries Limited' and is seeking shareholder approval to waive the recovery of ₹25.19 lakhs in excess managerial remuneration paid in FY26. Additionally, remuneration for key directors has been revised upwards, with the Whole-time Director's salary set at ₹8 lakhs per month plus allowances.
Confidence: HIGH
What changedThe company is undergoing a rebranding to Pasura Industries and has replaced its secretarial auditor while reporting a significant drop in quarterly profitability.
Why it mattersThe rebranding may indicate a strategic shift, but the request to waive excess director remuneration and the simultaneous increase in director pay despite falling profits raises governance and capital allocation concerns.
Revenue (Q1 FY27): ₹820.00 LakhsNet Profit (Q1 FY27): ₹61.24 LakhsExcess Remuneration Waiver: ₹25.19 LakhsWTD Monthly Salary: ₹8.00 LakhsAGM Date: 12th August 2026
📅 Short termThe stock may face pressure due to the 70% YoY profit decline and governance-related proposals regarding director pay.
📈 Long termThe long-term outlook depends on whether the rebranding to Pasura Industries leads to improved operational efficiency or market expansion, as current margins are deteriorating.
⚠ Risk flags
- Governance risk regarding waiver of excess managerial remuneration
- Significant YoY decline in net profit margins
- Change in secretarial auditors
Key Highlights
Net profit after tax fell to ₹61.24 lakhs in Q1 FY27 from ₹204.54 lakhs in the same quarter last year.
Revenue from operations decreased to ₹820.00 lakhs compared to ₹871.24 lakhs YoY.
Board approved a waiver for the recovery of ₹25.19 lakhs in excess remuneration paid to two directors in FY 2025-26.
Proposed name change to 'Pasura Industries Limited' subject to member approval at the upcoming AGM.
Secretarial Auditor changed from Manoj Parakh & Associates to Vivek Surana & Associates effective July 9, 2026.
👀 What to Watch
Investors should monitor the 40th AGM on August 12, 2026, specifically the voting outcomes on the name change and the waiver of excess managerial remuneration. The sharp decline in margins despite relatively stable revenue requires scrutiny of the 'Other Expenses' which rose to ₹313.28 lakhs.
₹61.24 Lakhs Q1 Profit; Name Change to Pasura Industries and Remuneration Revisions Approved
Arunjyoti Bio Ventures reported a sharp 70% YoY decline in net profit to ₹61.24 Lakhs for Q1 FY27, down from ₹204.54 Lakhs in Q1 FY26. Revenue from operations also saw a slight contraction of 5.9% YoY to ₹820.00 Lakhs. The board has approved a strategic name change to 'Pasura Industries Limited' and proposed significant revisions to director remuneration, including a monthly salary of ₹8 Lakhs for the Whole-time Director. Additionally, the company waived the recovery of ₹25.19 Lakhs in excess managerial remuneration paid during FY 2025-26, subject to shareholder approval.
Confidence: HIGH
What changedThe company is undergoing a rebranding to Pasura Industries and has restructured its management compensation and secretarial audit firm.
Why it mattersThe significant drop in net profit margins (from ~23% to ~7.5% YoY) combined with increased fixed costs for director remuneration may pressure future bottom-line performance.
Net Profit (Q1 FY27): ₹61.24 LakhsRevenue from Operations (Q1 FY27): ₹820.00 LakhsYoY Profit Growth: -70.06%Excess Remuneration Waiver: ₹25.19 LakhsProposed MD Monthly Salary: ₹8.00 Lakhs
📅 Short termThe stock may face pressure due to the weak earnings performance and the optics of increasing management pay while profits are declining.
📈 Long termThe rebranding to Pasura Industries suggests a new corporate identity, but long-term value will depend on stabilizing margins in the co-packing business.
⚠ Risk flags
- Significant margin compression
- Substantial increase in managerial remuneration
- Resignation of Secretarial Auditor
Key Highlights
Net profit declined by 70.06% YoY to ₹61.24 Lakhs for the quarter ended June 30, 2026.
Revenue from operations decreased to ₹820.00 Lakhs compared to ₹871.24 Lakhs in the corresponding quarter last year.
Board approved a waiver for the recovery of ₹25.19 Lakhs in excess managerial remuneration paid in FY 2025-26.
Proposed upward revision of director remuneration to ₹8 Lakhs and ₹5 Lakhs per month for key Whole-time Directors.
Change of company name to Pasura Industries Limited approved, pending member and regulatory consent.
👀 What to Watch
Investors should monitor the upcoming AGM on August 12, 2026, specifically the shareholder voting results on the name change and the substantial increase in managerial compensation despite falling profits.
